

## **Information for Healthcare Professionals:**

Lovenox® (enoxaparin sodium injection) for Subcutaneous and Intravenous Use

### **Important Revisions to the Prescribing Information**

According to MedWatch, modifications have been made to the CONTRAINDICATIONS, WARNINGS & PRECAUTIONS, ADVERSE REACTIONS and USE IN SPECIFIC POPULATIONS sections of Lovenox® labeling. The revised CONTRAINDICATIONS section now addresses known hypersensitivity to enoxaparin sodium (e.g., pruritus, urticaria, anaphylactoid reactions). The WARNINGS & PRECAUTIONS section has been modified to address percutaneous coronary revascularization procedures. The USE IN SPECIFIC POPULATIONS section states that when used in the prevention of DVT in hip, knee and abdominal surgery; treatment of DVT, and prevention of ischemic complications of unstable angina and non-Q-Wave myocardial infarction, Lovenox® should be used with care in geriatric patients who may show delayed elimination of enoxaparin. In addition, caution should be exercised when administering enoxaparin to patients with hepatic impairment.

The complete MedWatch Safety Labeling Changes, including links to prescribing information, are available at:

<http://www.fda.gov/medwatch/SAFETY/2007/may07.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS Web site at [http://www.spine.org/spine\\_safety\\_notices.cfm](http://www.spine.org/spine_safety_notices.cfm). This information is provided as a service for information and education only.